OrthoPediatrics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by OrthoPediatrics Corp. on May 24, 2024. The filing details the outcomes of four specific proposals submitted to security holders for a vote.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to corporate governance voting results.
Material Changes and Voting Results
The following matters were approved by stockholders:
- Election of Directors: Three nominees were elected to serve until the 2027 Annual Meeting.
- David R. Bailey: 18,199,037 votes for; 1,790,600 votes withheld.
- Marie C. Infante: 12,686,531 votes for; 7,186,996 votes withheld.
- Jimmy D. McDonald: 14,265,857 votes for; 5,721,728 votes withheld.
- Executive Compensation (Say-on-Pay): Stockholders approved the advisory compensation of named executive officers with 19,430,742 votes for and 258,906 votes against.
- 2024 Incentive Award Plan: Stockholders approved the new incentive plan with 18,409,907 votes for and 1,279,054 votes against.
- Appointment of Auditors: Stockholders approved the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 20,565,406 votes for and 150,366 votes against.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Note the significant number of votes withheld for director nominee Marie C. Infante (7,186,996) compared to the other nominees.
- Confirm the effective date and specific terms of the newly approved 2024 Incentive Award Plan in subsequent filings.
- Review the full proxy statement for detailed biographical information on the elected directors and the rationale behind the executive compensation package.